Capricor Therapeutics, Inc. (CAPR)

Market Cap	170.43M
Revenue (ttm)	25.18M
Net Income (ttm)	-22.29M
Shares Out	31.50M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	638,686
Open	5.14
Previous Close	5.15
Day's Range	5.12 - 5.49
52-Week Range	2.68 - 8.22
Beta	4.04
Analysts	Strong Buy
Price Target	24.00 (+342.8%)
Earnings Date	May 9, 2024

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 101
• Stock Exchange: NASDAQ
• Ticker Symbol: CAPR

Financial Performance

In 2023, CAPR's revenue was $25.18 million, an increase of 886.81% compared to the previous year's $2.55 million. Losses were -$22.29 million, -23.20% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CAPR stock is "Strong Buy." The 12-month stock price forecast is $24.0, which is an increase of 342.80% from the latest price.

Price Target

$24.0

(342.80% upside)

Analyst Consensus: Strong Buy